Life opra

Author: p | 2025-04-24

OPRA Implant System Get your life back with the OPRA Implant System. The OPRA Implant System is an innovative method allowing the direct connection of an artificial limb to Join us as we explore the extraordinary life of Opra, celebrating her achievements and the lessons learned along the way. What is Opra's Biography? Opra Winfrey, born on

Discovering The Enigma Of Opra: A Journey Through Life And

This survey. The consolidation arms of these trials demonstrated significantly higher rates of pCR (AIO-12) or cCR (OPRA) when compared to induction chemotherapy. In addition, 53% of patients in the consolidation arm of the OPRA trial avoided surgery at 3-year follow-up making this regimen attractive for those aiming for non-operative management (NOM), an approach that can improve quality of life by reducing low anterior resection syndrome (LARS). However, it must be noted that neither of these phase 2 trials significantly improved DFS or OS, and most centres do not recommend NOM unless as part of a clinical trial. Notably, at the American Society of Clinical Oncology (ASCO) 2023 conference, the 5-year OPRA update showed persistent differences in organ preservation using the consolidation approach (54% vs 39% with induction TNT) and lower rates of local regrowth (29% vs 44% with induction TNT). Furthermore, there was no oncologic detriment in either arm when integrating a watch-and-wait approach with salvage surgery for regrowth [18].More than 60% of colorectal surgeons in this survey preferred a consolidation TNT approach, despite historical concerns about the potential risk of pelvic fibrosis as the time interval between radiation and surgery is extended. The French GRECCAR-6 trial showed greater surgical complications and morbidity when waiting for 11 weeks, as opposed to 7, after neoadjuvant chemoradiotherapy, which may partly explain the preference for the induction PRODIGE regimen in France. However, several trials have not demonstrated increased surgical difficulty or compromised R0 resection rates with a consolidation TNT approach [19,20,21].Specialists in this survey demonstrated a low preference for the PRODIGE regimen, especially for advanced-risk disease for which it was chosen by less than 10%, surprising considering the robust data supporting this approach. PRODIGE-23, a phase 3, randomized controlled trial of induction FOLFIRINOX chemotherapy followed by LCCRT, demonstrated superior pCR rates (28% vs 12%, p p = 0·034) and metastasis-free survival (hazard ratio 0·64, p = 0·017) compared to LCCRT alone. Furthermore, since conducting our survey, additional follow-up data presented at ASCO 2023 demonstrated a significant increase in 5-year overall survival (6.9%), the only TNT trial to do so [22].In the setting

Exploring The Life And Legacy Of Opra: A Journey Beyond The

Approach for a patient with a stage II-III ESMO EARLY (GOOD) risk category rectal cancer (cT3a/b in mid- or high rectum, N0 (or also cN1 if high), MRF clear, no EMVI). a. Upfront surgery b. Short course radiotherapy (SCRT) followed by surgery c. Long-course chemoradiotherapy (LCCRT) followed by surgery d. Total Neoadjuvant Therapy (TNT) If choosing a TNT approach, which protocol would you prefer in this case? a. PRODIGE 23 (FOLFIRINOX – LCCRT – Surgery – FOLFOX) b. RAPIDO or STELLAR (SCRT – FOLFOX or CAPOX – Surgery) c. Induction OPRA or CAO/ARO/AIO-12 (FOLFOX – LCCRT – Surgery) d. Consolidation OPRA or CAO/ARO/AIO-12 (LCCRT – FOLFOX – Surgery) Case 2 – Indicate your preferred approach for a patient with an ESMO INTERMEDIATE risk category rectal cancer (cT3a/b if low rectum, levators clear, MRF clear OR cT3a/b in mid- or high rectum, cN1-2 (not extra-nodal), no EMVI). a. Upfront surgery b. Short course radiotherapy (SCRT) followed by surgery c. Long-course chemoradiotherapy (LCCRT) followed by surgery d. Total Neoadjuvant Therapy (TNT) If choosing a TNT approach, which protocol would you prefer in this case? a. PRODIGE 23 (FOLFIRINOX – LCCRT – Surgery – FOLFOX) b. RAPIDO or STELLAR (SCRT – FOLFOX or CAPOX – Surgery) c. Induction OPRA or CAO/ARO/AIO-12 (FOLFOX – LCCRT – Surgery) d. Consolidation OPRA or CAO/ARO/AIO-12 (LCCRT – FOLFOX – Surgery) Case 3 – Indicate your preferred approach for a patient with an ESMO BAD risk category rectal cancer (cT3c/d or very low localisation, levators threatened, MRF clear OR cT3c/d mid-rectum, cN1–N2 (extra-nodal), EMVI + OR limited cT4aN0). a. Upfront surgery b. Short course radiotherapy (SCRT) followed by surgery c. Long-course chemoradiotherapy (LCCRT) followed by surgery d. Total Neoadjuvant Therapy (TNT) If choosing a TNT approach, which protocol would you prefer in this case? a. PRODIGE 23 (FOLFIRINOX – LCCRT – Surgery – FOLFOX) b. RAPIDO or STELLAR (SCRT – FOLFOX or CAPOX – Surgery) c. Induction OPRA or CAO/ARO/AIO-12 (FOLFOX – LCCRT – Surgery) d. Consolidation OPRA or CAO/ARO/AIO-12 (LCCRT – FOLFOX – Surgery) Case 4 – Indicate your preferred approach for a patient with an ESMO

GitHub - opra-project/OPRA: OPRA is an open, community

To downsize the primary tumour to improve surgical margins and provide a route to non-operative management (NOM) in selected patients with a complete clinical response.Recently, multiple clinical trials, such as OPRA, PRODIGE-23 and RAPIDO, have demonstrated the benefits of TNT including an increased rate of clinical (cCR) and pathological complete response (pCR), improved disease-free survival (DFS) and the facilitation of NOM [7,8,9]. Although patient inclusion criteria and TNT regimens differed between the trials, the overall benefits are supported by a meta-analysis of eight studies totaling over 2000 patients [10]. As such, TNT is broadly recommended by the National Comprehensive Cancer Network (NCCN) for > T3 tumours, any node-positive disease or an involved or threatened circumferential margin [11]. On the other hand, the European Society of Medical Oncology (ESMO) rectal cancer guidelines predate the publication of many landmark TNT trials, and therefore, TNT does not feature prominently [12]. Furthermore, not all rectal cancer specialists are proponents of TNT given the lack of longer-term outcome data, especially overall survival (OS), as well as concerns of overtreatment [13, 14].The primary goal of this survey therefore was to determine the TNT preferences of specialists attending the All-Ireland Colorectal Cancer Conference (AICCC) 2022, including the lead investigators of the influential OPRA, PRODIGE-23 and RAPIDO trials.MethodsWe conducted a survey of colorectal surgery (CRS), radiation oncology (RO) and medical oncology (MO) specialists attending the national AICCC, an in-person-only event on 14 October 2022. An overview of the methodology is presented in Fig. 1.Fig. 1Overview of the survey methodologyFull size imagePrior to the survey, conference attendees received a 90-min education session on rectal cancer featuring updates from lead investigators of OPRA, PRODIGE and RAPIDO. In the next session, these speakers formed an expert multidisciplinary panel consisting of 2 colorectal surgeons, 1 radiation oncologist, 3 medical oncologists and a radiologist. The current NCCN, ESMO and ASTRO guidelines were reviewed before 4 rectal cancer cases, including the history, radiology and histopathology that were presented to the panel in front of the live audience. The cases were formulated and agreed beforehand by the conference organizing committee, which consisted of a consultant. OPRA Implant System Get your life back with the OPRA Implant System. The OPRA Implant System is an innovative method allowing the direct connection of an artificial limb to

OPRA - Stock Quotes for OPRA Ent Holdg, NASDAQ: OPRA

The latest appliance is purpose-built to reliably handle rising market data volumes and volatility, including the upcoming OPRA feed upgradeSt. Louis, MO— August 23rd, 2023 – Exegy, a leading provider of end-to-end, front-office trading solutions for capital markets, is announcing its next generation ticker plant, purpose-built for processing options market data. This cutting-edge platform can process the OPRA feed on a single 2U server and provides an immediate 2x latency reduction compared to the previous generation.This 6th generation ticker plant is the foundation for future latency improvements and feature updates, continuing its 15+ year history as the ideal, managed market data solution for the industry’s top brokers, trading venues, and global hedge funds.With ever-increasing options trading volumes and the new OPRA feed going live on October 9th, the ability to reliably process growing quantities of market data with consistent, low latency is critically important for the trading community. Exegy’s unique, FPGA-based, managed appliance has scalability that cannot be matched by fully software-based solutions.David Taylor, CEO of Exegy, says: “The sustained volatility in capital markets continues to drive market data volumes to new historic peaks, especially in the US equity options markets. The OPRA consolidated tape doubling its data streams and new options markets coming online imminently further increases the pressure on existing market data infrastructures.”By the end of 2022, US stock options surpassed 10 billion contracts, with single-stock and index options volumes more than doubling since 2019. Now, OPRA’s guidance states that participants should prepare for capacity of 120+ million messages per second following the expansion.Arnaud Derasse, CPO at Exegy, adds: “Trading institutions need to boost capacity regularly with scalable and resilient infrastructure to keep pace with data volumes. This is particularly true for US options trading today. Exegy’s latest generation ticker plant offers the most compact and efficient solution,

Unveiling The Enigma Of Opra: A Journey Through Life And Legacy

Open Public Records Act (OPRA)To obtain the OPRA Form, CLICK HEREState of New Jersey, Government Records CouncilCommon LawA public record under common law is one required to be kept, or necessary to be kept in discharge of a duty imposed by law, or directed by law to serve as a memorial and evidence of something written, said, or done, or a writing filed in a public office. The elements essential to constitute a public record are that it be a written memorial, that it be made by a public officer, and that the officer be authorized by law to make it.If the information requested is a "public record" under common law and the requester has a legally recognized interest in the subject matter contained in the material, then the material must be disclosed if the individual's right of access outweighs the State's interest in preventing disclosure.Note that any challenge to a denial of a request for records under common law cannot be made to the Government Records Council, as the Government Records Council only has jurisdiction to adjudicate challenges to denials of OPRA requests. A challenge to the denial of access under common law can be made by filing an action in Superior Court.What is the Open Public Records Act (OPRA)? What to do if your request has been denied?If you wish to have copies of any of these records the fees are:· $0.05 per page for letter sized pages and smaller· $0.07 per page for legal sized pages and larger· For delivery, all fees will be based upon the type of delivery requested and the fee will be added to page costs.· Extraordinary service fees are dependent upon the request (i.e. computer disc, CD-ROM, DVD).· Payment may be in the form of cash, check or money order.

OPRA - Stock Quotes for OPRA Ent Holdg, NASDAQ: OPRA - Webull

Ticker-mobile-nav#onScroll" data-controller="ticker-mobile-nav">Ratings - OPRADividend Safety?Years of consecutive dividend increase.Returns Potential?Price target upside according to sell-side analysts.Quant Recommendation - OPRARatings analysis incomplete due to data availability. Recommendations not provided.OPRA Payout History (Paid, Declared and Estimated)YearCalendar Year Payout (USD)Calendar Year Payout Growth (USD)Pay DateDeclared DateEx-dividend DatePayout Amount (USD)Qualified Dividend?Payout TypeFrequencyDays Taken For Stock Price To RecoverYield on Cost2025e--2025-01-132024-12-122025-01-06$0.4000Non-QualifiedRegularSemi Annually-2.07%2024$0.81001.250%2024-07-152024-06-112024-07-02$0.4100Non-QualifiedRegularSemi Annually-3.22%2024-01-092023-12-122024-01-02$0.4000Non-QualifiedRegularSemi Annually-3.15%2023$0.8000-2023-07-122023-06-142023-06-29$0.4000Non-QualifiedRegularSemi Annually-2.06%2023-02-092023-01-122023-01-27$0.8000Non-QualifiedUnknown--11.90%OPRA Dividend Growth CAGRYearAmount (USD)1Y (USD)3Y (USD)5Y (USD)10Y (USD)20Y (USD)2024$0.811.25%N/AN/AN/AN/A2025$0.40N/AN/AN/AN/AN/A2026N/AN/AN/AN/AN/AN/ADividend capture strategy is based on OPRA’s historical data. Past performance is no guarantee of future results.Step 1: Buy OPRA shares 1 day before the ex-dividend datePurchase Date (Estimate)N/AUpcoming Ex-Dividend DateN/AStep 2: SEll OPRA shares when price recoversAvg Price Recovery25.5 DaysSee Full HistoryNews & ResearchNewsSorry, there are no articles available for this stock.ResearchSorry, there are no articles available for this stock.Company ProfileCompany OverviewNo company description available.© 2020 Market data provided is at least 15-minutes delayed and hosted by Barchart Solutions.Information is provided ‘as is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please see disclaimer

OPRA - Stock Quotes for OPRA Ent Holdg, NASDAQ: OPRA Stock

ADVANCED (UGLY) risk category rectal cancer (cT3 with any MRF involved, any cT4a/b, lateral node +). a. Upfront surgery b. Short course radiotherapy (SCRT) followed by surgery c. Long-course chemoradiotherapy (LCCRT) followed by surgery d. Total Neoadjuvant Therapy (TNT) If choosing a TNT approach, which protocol would you prefer in this case? a. PRODIGE 23 (FOLFIRINOX – LCCRT – Surgery – FOLFOX) b. RAPIDO or STELLAR (SCRT – FOLFOX or CAPOX – Surgery) c. Induction OPRA or CAO/ARO/AIO-12 (FOLFOX – LCCRT – Surgery) d. Consolidation OPRA or CAO/ARO/AIO-12 (LCCRT – FOLFOX – Surgery) ResultsOne hundred and seventy delegates attended the AICCC including 17 colorectal surgeons (CRS), 7 radiation oncologists (RO) and 21 medical oncologists (MO). Forty-five participants answered at least one question in the survey. Thirteen were excluded from subsequent analysis as they did not specify their specialty. The response rate was therefore 71%. Data was 95% complete for this group.Early riskSeventy-seven percent (24/31) of all specialists preferred an upfront surgery approach whilst neoadjuvant LCCRT and SCRT were preferred by 10% each (Fig. 3A). CRS and RO almost unanimously chose upfront surgery whereas MO were split between upfront surgery (50%) and a form of neoadjuvant radiation (40%) (p = 0.41) (Fig. 3B). Just one participant selected TNT for early-risk rectal cancer.Fig. 3Preferred treatment approaches to ESMO rectal cancer risk categories, A all participants, B–E by specialistFull size imageIntermediate riskThe greatest heterogeneity of responses was observed in this category. Just over half of respondents (16/30) indicated a preference for TNT whilst a third chose LCCRT as the preferred neoadjuvant strategy. Seven percent of specialists opted for SCRT with another 7% preferring upfront surgery. TNT was selected most prominently by MO (71%) whilst LCCRT was most popular amongst RO (57%) and CRS (44%) (p = 0.30) (Fig. 3C).If utilizing a TNT approach, 55% (17/31) selected a consolidation-type (OPRA or CAO/ARO/AIO-12) regimen, 23% a RAPIDO or STELLAR regimen, 16% PRODIGE-23 and 6% an induction-type (OPRA or CAO/ARO/AIO-12) regimen (Fig. 4A). The majority of CRS and RO preferred a consolidation regimen whilst MO were divided between consolidation (40%) and a RAPIDO or STELLAR regimen. OPRA Implant System Get your life back with the OPRA Implant System. The OPRA Implant System is an innovative method allowing the direct connection of an artificial limb to

OPRA Partnership Opportunity 2025 OPRA Women in

=G$141J146 & J147 = the number of days to the proposed expiration date:J146 & J147: =IF(NOW()>=I146+”15:00:00″,”Expired”,DATEDIF(TODAY(),I146,”d”))D145 = one Standard Deviation below the current value of the underlying asset. My Short-Strike must be this value or less.D145 =L145-(L145*T147*SQRT(J146/365)) (assuming a put spread). (see post “Entry Rules for a Vertical Bull Put Credit Spread” for details on how to calculate SD.)D149 = Strike’s delta difference as shown on the Option Chain (the difference from one Strike to the next). For DIA there is a 5-point difference between Strikes.D149: 5D146 = the suggested Short Strike based upon my Entry Rules for a Vertical Bull Put Credit Spread. This is a calculated value using the “FLOOR” function of Excel:D146: =FLOOR(D145,D149)+E148D147 = the suggested Long Strike.D147: =D146+D142Create OPRA Code NameE146 = the OPRA code for the calculated Short Strike Put Option:E146: =IF(D146=””,””,”.”&E145&TEXT(I146,”YYMMDD”)&LEFT(B146,1)&D146)E147 = the OPRA code for the calculated Long Strike Put OptionE147: =IF(D147=””,””,”.”&E145&TEXT(I147,”YYMMDD”)&LEFT(B147,1)&D147)I can now use these OPRA IDs with ToS to pull options-specific data for the rest of my subsections. Performance Data For My Prospective SpreadThis subsection will show how to:Calculate the Mark Premium Price for the Vertical Spread.Display the Probability the Short Strike will expire Out-of-The-Money (OTM).Display the Probability the asset value will “touch” the Short Strike.Display the percentage the underlying asset have to fall before going ITM with the Short StrikeDisplay the Implied Volatility (IV) of the underlying asset.Retrieve the Current Asset PriceL145 = The current price of the Spreads’ underlying assetL145: =IF(E145=””,””,RTD(“tos.rtd”,,”LAST”,E145))Get the Spread’s Premium price:M146 = the Bid price of the Short-Strike leg. This will be a positive value =IF($E146=””,””,RTD(“tos.rtd”,,”BID”,$E146)*IF(C146>0,-1,1))M147 = the Bid price of the Long-Strike leg. This will be a negative value.M147: =IF($E147=””,””,RTD(“tos.rtd”,,”BID”,$E147)*IF(C147>0,-1,1))O146 = the Ask price of the Short-Strike leg. This will be a positive valueO146: =IF($E146=””,””,RTD(“tos.rtd”,,”ASK”,$E146)*IF(C146>0,-1,1))O147 = the Ask price of the Long-Strike leg. This

OPRA - Ohio Parks and Recreation Association (OPRA)

The Prospective SpreadPerformance Data For My Prospective SpreadDollars and CentsDescribe the Prospective SpreadThis section will show how to:Calculate a value 1-Standard Deviation below the current value of the underlying asset.Calculate a recommendation for a Short Strike that is more than 1-SD below asset value.Determine what the Long Strike will be.Assemble the OPRA (Options Price Reporting Authority) designators for the long and short strikes puts used in my prospective spread. As shown from the screen-captured images below, the calculated OPRA IDs will be “.DIA210702P320” and “.DIA210702P300”. I can then use these cells in the rest of this block to retrieve performance and price information.General input affecting all prospective Spreads:G141 = the Expiration date (literal date manually entered). This date value will be used with all the speculative spreads within this section.G141: 7/2/2021D142 = the Strike Width of these prospective spread positions (literal/manual entered). This will be used with all speculative spreads within this section.D142: 20Basic Spread Configuration:E145 = the underlying asset I am investigating. This is a literal entry.E145: DIAB146 & B147 = the Options type based upon the selected strategy (Puts for the Vertical Put Spread). These are literals but could be calculated based on the value of B145.B146: PutB147: PutA146 & A147 identify the row as being the “Short” Strike or “Long” Strike leg of the spread. These are literals but could be calculated based on the value of B145.A146: ShortA147: LongC146 & C147 = the number of contracts that I propose. They both need to be numerical the same. C146 is the number of Short Strikes I will be selling (-) and C147 is the number of Long Strikes I will be buying (+).C146: -1C147: 1H146 & H147 = the proposed date to open this spread:H146 & H147: =TODAY()I146 & I147 = the proposed Expiration Date:I146 & I147:. OPRA Implant System Get your life back with the OPRA Implant System. The OPRA Implant System is an innovative method allowing the direct connection of an artificial limb to

Opra Surname Meaning Opra Family History at Ancestry.com

In each specialty. The cases described stage II or III early (good), intermediate, bad, and advanced (ugly) risk categories of rectal cancer according to the ESMO clinical practice guidelines [12, 15, 16]. Stage I tumours were not discussed as TNT which has no role to play in this context.After the MDT panel had debated each case, all the CRS, RO and MO specialists attending the conference were invited to take part in a live, anonymous survey. Participants were informed that the survey was voluntary and were asked to provide their consent before proceeding. The survey consisted of four sections, each representing an ESMO rectal cancer risk category with TNM, extramural venous invasion (EMVI) and circumferential resection margin (CRM) descriptions provided. Each section asked the participant two multiple-choice questions: firstly, what was their preferred treatment approach for that category (upfront surgery, short-course radiotherapy (SCRT), long-course chemo-radiotherapy (LCCRT) or total neoadjuvant therapy (TNT)); secondly, if TNT was employed, what was their preferred regimen (PRODIGE 23, RAPIDO or STELLAR, induction OPRA or CAO/ARO/AIO-12, or consolidation OPRA or CAO/ARO/AIO-12). A description of the sequence of each regimen was provided. The survey is displayed in Fig. 2.Fig. 2Survey questionsFull size imageThe survey was administered using online polling software (www.slido.com), accessed by the participant on their smartphone using a survey-specific code. Participants were familiarized with this software at the beginning of the conference with two practice questions. All participants were surveyed simultaneously with a maximum of 60 s allowed to respond to each question. Participants could only select one answer and undertake the survey once. The results of each question were subsequently displayed on the main conference screen to provide instant feedback to the audience.Anonymized responses were downloaded into Microsoft Excel for coding. The rate of non-responses to each question was recorded. To improve validity, only respondents that confirmed their specialty were included in the final analysis. Descriptive statistics, chi-square/Fisher’s exact tests were performed using IBM SPSS statistics version 29. This survey is reported in accordance with the CROSS guidelines [17].Please indicate your specialty: Colorectal surgery Radiation Oncology Medical Oncology Case 1 – Indicate your preferred